StockTipsArenaBeta

BUY Lupin Limited — Manas Jaiswal

BUYLupin Limited
Lupin share price target & all analyst calls

byManas JaiswalHorizon: NA (inferred 1–3 months)13 May 2026via CNBC Awaaz.

Entry₹2,200Stated
Target₹2,500
Total upside +13.64% (call closed)
Stop loss₹2,100-4.55% risk
Exit—No position was opened
ExpiredNAauction close
Follow Manas Jaiswal for new calls(36% target hit, 36 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 3 active Short-term calls on LUPINSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 13 Aug 2026
36 supporting3 neutral8 opposing
Supports the BUY call (36)

Lupin wins US FDA nod for sodium zirconium cyclosilicate to treat hyperkalemia

NewsCnbc-Tv18·10 Aug · 2d ago

(opens in new tab)

Lupin announced that its Sodium Zirconium Cyclosilicate for Oral Suspension has been approved in the United States.

BSE · Company Update·10 Aug · 2d ago

(opens in new tab)

6 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·10 Aug · 3d ago

Lupin Q1 PAT rises 16 pc at Rs 1,417 cr

NewsEt-Markets·7 Aug · 5d ago

(opens in new tab)

Lupin Q1 results driven by strong US sales; stock slips from day's high

NewsCnbc-Tv18·7 Aug · 6d ago

(opens in new tab)
Neutral / worth noting (3)

Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price

NewsNdtv-Profit·10 Aug · 3d ago

(opens in new tab)
Weighs against the BUY call (8)

1 advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·9 Aug · 4d ago

US tariff threat drags Nifty Pharma 1.3% lower at close; Lupin, PPL Pharma lead decline

NewsHbl·22 Jul · 3w ago

(opens in new tab)

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 3w ago

(opens in new tab)

Gland Pharma, Lupin, Dr Reddy's: All Nifty Pharma Stocks In Red After Trump's Drug Tariff Plan

NewsNdtv-Profit·22 Jul · 3w ago

(opens in new tab)

Lupin, Sun Pharma to Cipla: Pharma stocks decline after Trump’s tariffs plan on generic medicines import

NewsLivemint·22 Jul · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Manas Jaiswal

Every call and its outcome